Особенности течения и терапии анемии при болезни Крона

Раздел только для специалистов в сфере медицины, фармации и здравоохранения!

Особенности течения и терапии анемии при болезни Крона

 1314

Особенности течения и терапии анемии при болезни Крона


Журнал "Медицинский совет. В поликлинике" № 12, 2018



В.А. Ахмедов, М.Н. Иванюк, Г.Р. Бикбавова, М.Р. Ибрагимова, А.Р. ИбрагимоваГБОУ ВПО «Омский государственный медицинский университет» Минздрава России

Одним из самых частых клинико-лабораторных проявлений и осложнений воспалительных заболеваний кишечника (ВЗК) является анемия. В представленном обзоре рассмотрены причины, критерии диагностики и терапевтической коррекции различных вариантов анемии при болезни Крона.

Features of the anemia at patients with crohn’s disease 

V.A. Akhmedov, M.N. Ivanyuk, G.R. Bikbavova, M.R. Ibragimova, A.R. Ibragimova, Omsk State Medical University of the Ministry of Health of the Russian Federation

One of the most frequent clinical and laboratory manifestations and complications of inflammatory bowel diseases (IBD) is anemia. In the presented review the reasons, criteria of diagnostics and therapeutic correction of various variants of anemia in Crohn’s disease are considered.

Особенности течения и терапии анемии при болезни Крона

 Загрузить файл


Список литературы

1. Ивашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И. и др. Диагностика и лечение взрослых пациентов с болезнью Крона (Рекомендации Российской гастроэнтерологической ассоциации по лечению болезни Крона у взрослых). Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2012, 6: 6

2. Болезнь Крона и язвенный колит. Под ред.

3. Г. Адлер. М.: ГЭОТАР-Мед, 2001: 527

4. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012, 142: 46-54. https://doi.org/10.1053/j.gastro.2011.10.001.

5. Неспецифические воспалительные заболевания кишечника. Под ред. Воробьева Г.И., Халифа И.Л. М.: Миклош, 2008: 400 с

6. Gisbert J, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol, 2008, 103: 1299-1307.

7. Kullnigg S, Gasche C. Systemic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther, 2012, 24: 1507-1523.

8. Ershler W, Chen K, Reyes E, Dubois R. Economic burden of patients with anemia in selected diseases. Value Health, 2005, 8: 629-638. https://doi.org/10.1111/j.1524-4733.2005.00058.

9. European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. Journal of Crohn’s and Colitis, 2014, 9: 211-222.

10. Revel-Vilk S, Tamary H, Broide E, Zoldan M, Dinari G, Zahavi I, Yaniv I, Shamir R. Serum transferrin receptor in children and adolescents with inflammatory bowel disease. Eur J Pediatr, 2000, 159: 585-589. https://doi.org/10.1007/ s004310000491.

11. Stein J, Hartmann F, Dignas A. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol, 2010, 7(11): 599-610.

12. Патофизиология системы крови: учебное пособие. Под ред. проф. В.Т. Долгих. О.: ОГМА, 2015: 112

13. Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol, 2007, 13: 4798-806.

14. Collins J, Wessling-Resnick M, Knutson M. Hepcidin regulation of iron transport. J Nutr, 2008, 138: 2284-2288. https://doi.org/10.3945/jn.108.096347.

15. Wrighting D, Andrews N. Interleukin-6 induces hepcidin expression through STAT3. Blood, 2006, 108: 3204-3209. https://doi.org/10.1182/blood-2006-06-027631.

16. Babior BM. Metabolic aspects of folic acid and cobalamin. Williams Hematology. 6-th Edition. 2001: 305-318.

17. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW, Kupcinskas L, Lakatos PL, Mantzaris GJ, Schreiber S, Villanacci V, Warren BF. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut, 2006, 55: 1-15. https://doi.org/10.1016/j.crohns.2007.11.001.

18. Weiss G,Goodnough LT. Anemia of chronic disease. N Engl J Med, 2005, 352: 1011-1023. https://doi.org/10.1056/nejmra041809.

19. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anemia, and inflammatory bowel diseases. Gut, 2004, 53: 1190-1197. https://doi.org/10.1136/ gut.2003.035758.

20. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta, 2003, 329: 9-22. https://doi.org/10.1016/ s0009-8981(03)00005-6.

21. Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition, 2006, 22: 1210-1213. https://doi.org/10.1016/j.nut.2006.08.017.

22. Green R. Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies. Am J Clin Nutr, 2011, 94: 666-672. https://doi.org/10.3945/ ajcn.110.009613.

23. Oustamanolakis P, Koutroubakis IE, Kouroumalis EA. Diagnosing anemia in inflammatory bowel disease: beyond the established markers. J Crohns Colitis, 2011, 5: 381-391. https://doi.org/10.1016/j.crohns.2011.03.010.

24. Khalil A, Goodhand JR, Wahed M, Yeung J, Ali FR, Rampton DS. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice. Eur J Gastroenterol Hepatol, 2011, 23: 1029-1035. https://doi.org/10.1002/ ibd.21846.

25. Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, Grännö C, Ung K, Hjortswang H, Lindgren A, Ungel P. Intravenous iron sucrose is superior to oral iron sulphate for correcting anemia and restoring iron stores in IBD patients: a random-ized, controlled, evaluator-blind, multicenter study. Scand J Gastroenterol, 2009, 44: 838-845. https://doi.org/10.1080/00365520902839667.

26. Gasche C ,Berstad ,Befrits R , Beglinger C, Dignass A, Erichsen K, Gomollon F, Hjortswang H, Koutroubakis I, Kulnigg S, Oldenburg B, Rampton D, Schroeder O. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis, 2007, 13: 1545-1553. https://doi.org/10.1002/ibd.20285.

27. Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, Iqbal T, Khalif I, Marteau P, Stein J, Gasche C. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol, 2013, 11: 269-277. https://doi.org/10.1016/j. cgh.2012.10.013.

28. Onken JE, Bregman DB, Harrington РА et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion, 2014, 54: 306-315.

29. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis, 2000, 6: 142-150.

30. Koutroubakis IE, Oustamanolakis P, Karakoidas C, Mantzaris GJ, Kouroumalis ЕА. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig Dis Sci, 2010, 55: 2327-2331.

31. Schroder O, Mickisch O, Seidler U et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol, 2005, 100: 2503-2509.

32. Kulnigg S, Stoinov S, Simanenkov V et al. Anovel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose [FERINJECT] randomized controlled trial. Am J Gastroenterol, 2008, 103: 1182-1192.

33. Bager P, Dahlerup. JF The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohns Colitis, 2010, 4: 427-430.

34. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxy-maltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology, 2011, 141: 846-53, e841-42.

35. Reinisch W, Staun M, Tandon RK, et al. A ran-domized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 [Monofer] compared with oral iron for treatment of anemia in IBD [PROCEED]. Am J Gastroenterol, 2013, 108: 1877-88.

36. Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica, 2010, 95: 199-205.

37. Katsanos K, Cavalier E, Ferrante M, et al. Intravenous iron therapy restores functional iron deficiency induced by infliximab. J Crohns Colitis, 2007, 1: 97-105.

38. Демихов В.Г., Скобин В.Б., Журина О.Н. Диагностика и лечение анемии, обусловленной дефицитом В12 (федеральные клинические рекомендации). Российский журнал онкогематологии, 2014, 4: 6

39. Vidal-Alaball J, Butler CC, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev, 2005, 3: CD004655.





Последние статьи